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ABSTRACT Low exercise tolerance has a large influence on
health status in chronic obstructive pulmonary disease and
chronic heart failure. In addition to primary organ dysfunction,
impaired skeletal muscle performance is a strong predictor of
low exercise capacity. There are striking similarities between
both disorders with respect to the muscular alterations underly-
ing the impairment. However, different alterations occur in dif-
ferent muscle types. Histologic and metabolic data show that
peripheral muscles undergo a shift from oxidative to glycolytic
energy metabolism, whereas the opposite is observed in the
diaphragm. These findings are in line with the notion that periph-
eral and diaphragm muscle are limited mainly by endurance and
strength capacity, respectively. In both diseases, muscular
impairment is multifactorially determined; hypoxia, oxidative
stress, disuse, medication, nutritional depletion, and systemic
inflammation may contribute to the observed muscle abnormali-
ties and each factor has its own potential for innovative treatment
approaches. Am J Clin Nutr2000;71:1033–47.
KEY WORDS Chronic obstructive pulmonary disease,
COPD, chronic heart failure, CHF, skeletal muscle, peripheral
muscle, respiratory muscle, exercise intolerance, muscle
performance, muscle morphology, muscle metabolism, hypoxia,
oxidative stress, medication, disuse, nutritional depletion, systemic
inflammation, oxygen therapy, antioxidant status, training,
nutritional support, anabolic steroids, review
INTRODUCTION
According to the definitions of the World Health Organiza-
tion, chronic diseases are characterized not only by the primary
impairments they cause, but also by the disabilities or even hand-
icaps that result from them (1). Although the primary impair-
ments in chronic obstructive pulmonary disease (COPD) and
chronic heart failure (CHF) clearly differ, there is a striking
resemblance in the systemic consequences of these diseases and
their effects on exercise capacity and health status (Figure 1).
Impaired skeletal muscle function in COPD and CHF has long
been ignored by focusing on the respective ventilatory and car-
diac limitations on exercise performance. Research has shown
that impaired skeletal muscle function is also an important pre-
dictor of exercise limitation in both diseases (2–6). Progression
of the primary impairments in these disorders can be slowed
down with medication (7, 8). Reversion can be only partially
achieved through surgical interventions such as lung volume
reduction surgery and lung transplantation (9, 10) and coronary
bypass surgery and heart transplantation (11). However, there are
limits on the age of most eligible patients and the availability of
donor organs for these interventions. In addition, such interven-
tions do not always confer a survival benefit; no improvement
was found after lung transplantation in patients with end-stage
emphysema (12). Also, irrespective of the reversibility of the
organ impairment, exercise intolerance in both COPD and CHF
remains after surgical intervention (13, 14), indicating that more
etailed insight into the systemic consequences is required for
effective treatment of these diseases.
Muscle function depends, though not completely, on perfu-
sion, muscle mass, fiber composition, and energy metabolism
(15). It can be inferred that alterations in one or more of these
determinants play a role in reduced muscle performance.
Indeed, such changes have been found in both COPD and CHF
and there are striking similarities between the 2 etiologically
distinct disorders.
In this review, we first present an overview of the clinical
studies that have investigated impaired muscle function, with
special emphasis on muscle morphology and energy metabolism
in COPD and CHF. The advantage of discussing both diseases
simultaneously is that the evidence about each complements
that of the other and therefore provides more insight into the
possible underlying causes of the muscle alterations. In the sec-
ond part of the article, potential causes will be discussed,
including hypoxia, oxidative stress, disuse, medication, nutri-
tional depletion, and systemic inflammation. The third part
deals with therapeutic perspectives.
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MUSCLE ALTERATIONS IN COPD AND CHF
Muscle performance
Muscle performance is characterized largely by strength and
endurance. Strength is defined as the capacity of the muscle to
develop maximal force, and endurance is defined as the capacity
of the muscle to maintain a certain force over time, thus, to resist
fatigue. Loss of either one of these aspects results in muscle
weakness and impaired muscle performance. Numerous studies
have now convincingly shown that COPD and CHF are com-
monly associated with muscle weakness (6, 16–21). Probably the
most extensive study on the influence of muscle weakness on
exercise capacity in cardiorespiratory disorders was done by
Hamilton et al (4). Compared with healthy subjects, patients
with respiratory failure, heart failure, or a combination of both
had significantly less strength in both peripheral and respiratory
muscles. However, strength and endurance seem not to be
affected in the same way in respiratory and peripheral muscles.
This is illustrated by the poor correlation between the strengths
of both muscle groups in the 2 disorders (18, 20, 21) compared
with the much stronger correlation in healthy subjects (22). This
implies that the strength component of muscle weakness is
affected differently in peripheral and respiratory muscles. In
healthy subjects as well as in patients with COPD or CHF,
exercise-limiting symptoms are the sense of leg effort (exer-
tional discomfort) or breathlessness (exertional dyspnea) (23, 24).
Thus, despite correlations between peripheral muscle strength
and performance in COPD and CHF (18, 23, 25), reduced
endurance (ie, fatigue) seems to be the dominant limiting factor
in peripheral muscles in these patients because the sense of leg
effort was one of the main reasons to stop exercising (4, 24,
26–29). It was shown that early lactic acidosis occurs in COPD
during exercise (30, 31) and that this is largely the result of lac-
tate release from the lower exercising limbs (32). Muscle acido-
sis is a contributing factor to muscle fatigue (33).
Fatigue is probably not the main limiting factor in respiratory
muscle function. Morrison et al (34) found that COPD patients
have low respiratory muscle strength and endurance. Fatigue of
the respiratory muscles may indeed occur during exercise, but it
is not certain whether this is an independent determinant of exer-
cise capacity (27, 35–38). In addition, it is unlikely that the res-
piratory muscles of exercising COPD patients contribute to the
lactate response mentioned earlier (39). It should also be empha-
sized that the respiratory muscles must operate against the
mechanical airway impedances in this specific disorder (40), for
which the force component of respiratory muscle function is
most likely of great importance. For CHF it was found that res-
piratory muscle strength and not respiratory muscle fatigability
correlated with the degree of dyspnea (41). Thus, it seems that
strength is the limiting aspect of muscle performance in the res-
piratory muscles, whereas endurance is limiting in peripheral
muscles. However, more detailed studies are required to clarify
the individual roles of strength and endurance limitation in
peripheral and respiratory muscles in COPD and CHF.
Muscle morphology
In both CHF (23, 42–44) and COPD (3, 45–50), marked loss
of muscle mass or decline in cross-sectional muscle area is
observed. This muscle wasting plays an important role in the loss
of exercise tolerance in these patients. However, morphologic
alterations may also be related to impairment of muscle function,
although direct relations with exercise performance have not yet
been shown. Some histologic information is available on abnor-
malities in skeletal muscle in CHF but there is hardly any on
COPD. Gertz et al (51) found no signs of increased fibrosis or
other alterations in intercostal muscles of patients with respira-
tory failure, whereas endomysial fibrosis has been found in
skeletal muscle of a limited number of CHF patients (52).
Increased activity of acid phosphatase, a lysosomal enzyme con-
tributing to protein degradation, has been found in the quadri-
ceps of some patients with CHF (25) or respiratory failure (50).
Increased lipid deposits have been found in the quadriceps,
biceps, and deltoids of some patients with CHF (25, 52). Con-
tradictory results have been obtained with respect to capillary
density in peripheral skeletal muscle in CHF. A normal capillary
density has been found (25), which agrees with results of 2 other
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studies in which both reduced capillary-fiber ratios and atrophy
resulted in unchanged capillary densities (53, 54). An unaltered
capillary-fiber ratio has also been reported, however, with greater
capillary density due to fiber atrophy (55). In contrast, reduced
capillary density in combination with a reduced capillary-fiber
ratio has been shown in CHF patients (56) and even in heart
transplant recipients (57). Thus, overall, there is a tendency
toward a reduced capillary-fiber ratio, but depending on the
degree of atrophy, the capillary density may even be elevated.
This tendency was recently confirmed in COPD (46).
In a few studies, morphometry of mitochondria with use of
electron microscopy showed that mitochondrial volume densities
in skeletal muscle were lower in CHF patients than in control
subjects (56, 58), and this was still the case 10 mo after heart
transplantation (57). Histochemical alterations reflecting mito-
chondrial abnormalities have also been reported in biceps mus-
cle biopsies of COPD patients (50). These results suggest that
the oxidative capacity of peripheral skeletal muscles may be
altered in both diseases.
Muscle fiber type distribution
Probably the most remarkable muscle alteration in COPD and
CHF is a relative shift in fiber composition that seems to occur in
opposite directions in peripheral and respiratory muscles. Fiber
typing is mainly performed histochemically, and is based on dif-
ferences between fibers in myosin ATPase activities or immuno-
cytochemistry (59). Adult mammalian skeletal muscle contains
4 myosin heavy chain (MyHC) isoforms, namely, types I, IIa, IIb,
and IIx (60). In most older studies, fiber typing was limited to
determining fiber types I, IIa, and IIb. Furthermore, human fibers
formerly identified as being IIb with myosin ATPase staining are
probably IIx fibers (61). Therefore, the notation IIb/x is used in
the subsequent text. Fiber type I has a slow twitch and develops a
relatively small tension, but because it depends mainly on aerobic
metabolism, it is fatigue resistant. In contrast, fiber type IIb/x has
a fast twitch and develops large tensions, but it is susceptible to
fatigue because its energy conversion is based on anaerobic, gly-
colytic metabolism. Fiber type IIa has intermediate properties in
that it also has a fast twitch, develops a moderate tension, is rela-
tively resistant to fatigue, and is apt to work under both aerobic
and anaerobic conditions (15, 59, 62).
A lower percentage of type I fibers and a corresponding
higher percentage of type II (mainly type IIb/x) fibers, compared
with those of normal subjects, has been reported in limb muscles
of COPD (46, 63–66) and CHF (25, 53–56, 67) patients. In addi-
tion, in one of these studies an increase in intermediate fiber
types (I + II) was also observed in CHF patients (55). These
fibers may represent transformation intermediates in the I→IIb/x
shift. In contrast with that in peripheral muscles, a shift from
type IIb/x to type I fibers has been reported in the diaphragms
of both COPD and CHF patients. In healthy subjects, the
diaphragm has <50% type I, 25% type IIa, and 25% IIb/x fibers
(68), whereas the diaphragms of CHF patients contain 60% type
I, 35% type IIa, and only 10% type IIb/x fibers (69). A IIb/x→I
shift was also observed when the distribution of MyHC isoforms
was analyzed in diaphragms of patients with CHF (70) or COPD
(71). Furthermore, a larger population of type I fibers in the
diaphragm (corrected for the percentage of type I fibers in the
quadriceps femoris) was found in both COPD and CHF patients
(26, 72) compared with sedentary control subjects (68, 73). The
proportion of type I fibers in both the internal and external inter-
costal muscles was <62% in both COPD patients and control
subjects in some studies (68, 74), but in other studies COPD
patients had lower proportions of type I fibers (46–48%) in these
muscles (73, 75). Also, elevated expression of fast MyHC has
been reported in the external intercostal muscles of COPD
patients (76). These results suggest that the accessory respiratory
muscles do not show the II→I fiber shift that occurs in the
diaphragm. No such data have been published for CHF patients.
The overall outcome of the studies done until now (despite
some variation in the results) has been that there is a I→IIb/x
shift in peripheral muscles and a IIb/x→I shift in the diaphragm
in COPD and CHF. It is possible that these shifts have functional
consequences in the affected muscles because the distinct fiber
types have different contractile properties with respect to twitch
and fatigue resistance. Therefore, in COPD and CHF, a I→IIb/x
hift accompanied by more glycolytic and less oxidative capac-
ity in peripheral muscles implies loss of fatigue resistance. This
change might contribute to the observed loss of exercise toler-
ance because peripheral muscle fatigue is the main exercise-lim-
iting factor in these patients. This was confirmed by a study in
which a faster twitch response in combination with less resis-
tance to fatigue was observed in the leg muscles of CHF patients
(77). Accordingly, a IIb/x→I shift toward more oxidative metab-
olism in the diaphragm implies a shift toward a more fatigue-
resistant but less strength-adapted muscle. This too is in line
with our notion that strength and not fatigue seems to be the
main limiting factor for respiratory muscle function.
Muscle metabolism
Much data are available on skeletal muscle metabolism in
CHF and COPD, partly because of the applicability of 31P-nuclear
magnetic resonance (31P-NMR), which has enabled a direct and
noninvasive assessment of tissue concentrations of high-energy
phosphates and pH. High concentrations of ATP, creatine phos-
phate (CrP), and nicotinamide adenine dinucleotide in the
reduced form (NADH) reflect a high-energy state, whereas ele-
vated concentrations of ADP, AMP, inorganic phosphate (Pi),
and oxidized nicotinamide adenine dinucleotide (NAD+) com-
monly reflect a low-energy state. Lactate and glycogen concen-
trations are often measured in muscle metabolism, but note that
low concentrations may reflect either increased clearance or
reduced formation, and vice versa for high concentrations.
Although activities of enzymes involved in muscle energy
metabolism measured in vitro do not reflect the physiologic sit-
uation because maximal activities are obtained under optimal,
artificial circumstances, they do provide an indication of adap-
tations in the expression of proteins involved in metabolic path-
ways. Typical oxidative enzymes are citrate synthase, succinate
dehydrogenase, and b-hydroxyacyl-CoA dehydrogenase (HAD).
Typical glycolytic enzymes are hexokinase, phosphofructoki-
nase, and lactate dehydrogenase—the latter of which catalyzes
the last step of anaerobic glycolysis.
Measurements of substrate and cofactor concentrations in
peripheral skeletal muscle of COPD and CHF patients indicate
impaired energy metabolism (Table 1). Most striking are the
observed reduced concentrations of high-energy phosphates at
rest. Pouw et al (81) observed the higher Pi-CrP and ADP-ATP
ratios were associated with slightly but statistically significantly
elevated inosine monophosphate (IMP) concentrations. The latter
may be due to increased degradation of accumulating AMP by
deamination, which probably reflects reduced aerobic capacity
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(83). The situation becomes even worse during exercise: a
greater increase in the Pi-CrP ratio and a faster drop in pH were
found in the calf muscle of COPD (47, 84, 85) and CHF (55, 86,
87) patients performing exercise than in healthy persons. Similar
results were obtained for the forearm muscle (14, 87–89). In
addition, a slower recovery of CrP concentrations was observed
after exercise in COPD and CHF patients than in healthy persons
(14, 47, 55, 85–89). These results suggest that rephosphorylation
of high-energy phosphates is less efficient in these patients, both
during and after muscular exercise. In addition, glycogen con-
tents in COPD and CHF patients tend to be lower, whereas lac-
tate concentrations are higher than in healthy persons (Table 1).
Thus, it seems that anaerobic energy metabolism is enhanced in
these diseases, and because this process yields far less ATP than
does complete oxidative degradation of glucose, this could
explain the reduced high-energy phosphate concentrations.
Analysis of enzyme activities also suggests an overall
increase in glycolytic and an overall decrease in oxidative activ-
ities in peripheral muscles of both COPD and CHF patients
(Table 2). Because these enzyme activities depend largely on the
fiber type (95), it is likely that this shift in activities is related to
the shift in fiber distribution mentioned above. Whether enzyme
activities adapt to the fiber type redistribution or the fiber type
redistribution adapts to enzyme activities remains unclear. In
addition to these chronic alterations of enzyme activities, which
are measured in vitro, there is probably also an acute effect on
the activities of these enzymes. As a consequence of impaired
electron transport, regeneration of NAD+ from NADH is reduced
and citrate synthase and HAD are inhibited by a high NADH-
NAD+ ratio (96). In addition, elevated AMP concentrations,
resulting from the inefficient rephosphorylation of ATP, stimu-
late glycolysis (96). However, note that this acute effect is invis-
ible in the in vitro activity measurements. In 2 studies, an addi-
tional inverse relation of oxidative enzyme activities with arterial
lactate concentrations was found during exercise, emphasizing
the assumed shift from oxidative toward glycolytic energy gen-
eration (30, 91). This loss of oxidative capacity probably
accounts for the above-mentioned lipid deposits (97) because
fatty acid consumption may be reduced while the supply of
blood fatty acids continues. Recently, activities of 2 other oxida-
tive enzymes, cytochrome-c oxidase (COX) and NADH dehy-
drogenase, were found to be elevated in COPD and CHF patients
(Table 2). On first notice, this seems to be paradoxical in light of
the observed reductions in the oxidative enzymes mentioned ear-
lier. However, the oxidative enzymes mentioned earlier are
involved in either the citric acid cycle or fatty acid oxidation,
whereas COX and NADH dehydrogenase are enzymes of the res-
piratory chain. COX interacts with oxygen and therefore is the
main determinant of mitochondrial oxygen affinity (98).
Because a correlation between COX activity and hypoxemia was
found (93), it may be that an increased number of COX mole-
cules is a mechanism that enhances the efficiency of residual
oxygen extraction and utilization and, thus, respiratory chain
function. In this study, COX-I (a mitochondrial encoded subunit
of COX) messenger RNA concentrations were not elevated but
mitochondrial 12S ribosomal RNA concentrations were. Because
this particular ribosomal RNA is a component of mitochondrial
ribosomes, which are involved in translation, mitochondrial pro-
tein synthesis may be enhanced. The mechanism of hypoxia
sensing and subsequent stimulation of mitochondrial gene
expression remains, however, unclear (93).
Because of technical difficulties with 31P-NMR and muscle
biopsies of the diaphragm and accessory respiratory muscles, lit-
tle is known about energy metabolism in these muscles. However,
the observed alterations in enzyme activities (Table 2) confirm the
morphologic data, in that oxidative enzyme activities are reduced
and glycolytic enzyme activities are elevated in COPD and CHF
compared with the healthy state. As in peripheral muscles, this
shift probably results from the shift in fiber type distribution.
POSSIBLE UNDERLYING FACTORS
Hypoxia
In COPD and CHF, oxygen delivery to peripheral and respi-
ratory muscles may be insufficient as a result of hypoxemia,
reduced blood supply, or both. In both cases, muscle tissue may
become hypoxic and this could lead to the adaptive changes in
skeletal muscle described above. In this respect, relevant infor-
mation is now available from mountaineering expeditions (last-
ing ≥ 6 wk above 5000 m), because oxygen is limited at this
altitude. Under these conditions, reductions in mitochondrial
volume densities, oxidative enzyme activities, and cross-sec-
tional areas of muscle fibers were found in the quadriceps
(99–101). Note, however, that such expeditions are accompa-
nied by strenuous physical activity, which also causes muscu-
lar adaptations other than those caused by hypoxia. In fact, the
effect of training in combination with hypoxia may even cause
a shift toward more oxidative metabolism (102). More infor-
mation about the effect of hypoxia on muscle has been obtained
from animal studies.
1036 GOSKER ET AL
TABLE 1
Muscle metabolite concentrations in chronic obstructive pulmonary
disease (COPD) and chronic heart failure (CHF)1
Direction relative
Metabolite and muscle to reference values References
Creative phosphate
QF (COPD) . 51, 64, 73, 782
QF (CHF) . 79, 802
IIC and EIC (COPD) . 51, 75
ATP
QF (COPD) . 51, 64, 73, 782
QF (CHF) . 79, 802
IIC and EIC (COPD) . 51, 75
IMP
TA (COPD) m 81
Glycogen
QF (CHF) . 53, 79, 80
QF (COPD) . 64, 732
Glucose
IIC and EIC (COPD) m 51
QF (CHF) . 82
Lactate
QF (COPD) m 51, 78
QF (CHF) m 82
IIC and EIC (COPD) m 51
Pyruvate
QF (CHF) m 53
1CrP, creatine phosphate; IMP, inosine monophosphate; QF, quadri-
ceps femoris; IIC, internal intercostal; EIC, external intercostal; TA, tib-
ialis anterior.
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Several animal studies have shown that hypoxia can indeed lead
to the muscular alterations described for the limb muscles of
COPD and CHF patients. For example, reduced fiber diameters in
combination with unaffected numbers of capillaries, resulting in
increased capillary densities, have been reported in rats exposed to
hypoxia (103–105). It is suggested that the availability of oxygen
to remaining muscle mitochondria is enhanced by this increased
capillary density in combination with the loss of oxidative capac-
ity (99). Furthermore, animal studies showed that hypoxia
depresses protein synthesis (106–109), even in muscle tissue (106,
107). Whether hypoxia itself can contribute to the shift in muscle
fiber distribution observed in COPD and CHF patients remains
uncertain. There is evidence that chronic hypoxia inhibits the nor-
mal conversion of type IIa to type I fibers in growing rats, with the
final outcome that these rats have a predominating proportion of
type IIa fibers, unlike in control rats (110–112). However, no dif-
ferences in fiber types were found when full-grown, adult rats
were exposed to chronic hypoxia (110, 111, 113). Thus, it seems
that hypoxia does not directly cause a type I→II fiber shift and it
is more likely that the abnormal fiber type distribution results from
alterations in muscular development. A similar mechanism may
underlie the abnormal fiber type distribution in the regeneration of
damaged muscle or the adaption of muscles to consequences of
the disease in COPD and CHF.
In addition, there is evidence that hypoxia causes a shift
toward glycolytic metabolism. In studies in which rats were
exposed to intermittent hypoxia, it was found that citric acid
cycle activity was reduced whereas glycolytic metabolism was
enhanced, resulting in an increased ratio of lactate to pyruvate
(114, 115). Malate dehydrogenase, a citric acid cycle enzyme,
was also found to be reduced by hypoxia (116). Furthermore,
hypoxia causes stimulation of glucose transport (117) and
increased concentrations of membrane-associated glucose trans-
porters (GLUT1 and GLUT4) in rat muscle (118). In muscle cell
cultures, this up-regulation of GLUT1 can be mediated by either
hypoxia or inhibition of the respiratory chain (119), suggesting
that hypoxia affects glucose transport (and probably also metab-
olism) via impairment of oxidative phosphorylation.
However, in COPD and CHF this reduction in oxidative
capacity does not occur in the diaphragm. Hypoxia may cause an
endurance training effect in the diaphragm because of increased
ventilation, which overrides its direct effect, ultimately resulting
in a shift toward more aerobic metabolism.
Oxidative stress
Oxidative stress may be another factor contributing to muscle
damage via reactive oxygen species. Increased plasma concen-
trations of lipid peroxidation products have been found in both
COPD and CHF patients (120, 121). The main source of these
oxygen free radicals is mitochondria because 2–5% of the oxy-
gen consumed is not fully reduced in the electron transport
chain and may leak away as superoxide radicals (122, 123). An
alternative source of free radicals is immune cells activated
during inflammation (124). Monocytes and macrophages pro-
duce the cytokine tumor necrosis factor a (TNF-a), which may
in turn induce oxidative stress in myocytes (125). Indeed, ele-
vated TNF-a blood concentrations have been found in both
COPD (126–128) and CHF (129–133) patients, particularly in
those patients with weight loss or muscle wasting. A third gen-
erator of free radicals is xanthine oxidase, which is involved in
the deamination of AMP to IMP under conditions of very high
AMP concentrations, such as a low-energy state (123). The
above-mentioned elevated IMP concentrations in COPD (81)
suggest enhanced AMP breakdown.
Susceptibility to these free radicals depends largely on the
antioxidant status of tissues (123). The main antioxidant scav-
engers and enzymes are, among others, reduced glutathione, vita-
min E (in cell membranes), superoxide dismutase, glutathione
peroxidase, and catalase (123, 134, 135). Repeated exposure to
oxidative stress, during long-term physical training for example,
stimulates the defense system against oxygen free radicals in that
concentrations of scavengers and activities of antioxidant
enzymes increase (122, 123, 134–136). Oxygen flux to muscles
and the resulting oxidative stress can increase tremendously dur-
ing exercise (123, 137) and the disuse of muscles thus may take
away this antioxidant-stimulating trigger and result in low antiox-
idant status. Chronic hypoxia probably acts in the same way
because less oxygen is available to form reactive oxygen species.
Limitations of oxygen supply are indeed found to be associated
with reductions in superoxide dismutase activity in mammalian
tissues like brain, lungs, and heart, although this change was not
SKELETAL MUSCLE DYSFUNCTION IN COPD AND CHF 1037
TABLE 2
Muscle enzyme activities in chronic obstructive pulmonary disease
(COPD) and chronic heart failure (CHF)1
Direction relative
Enzyme and muscle to reference values References
CS
QF (COPD) . 30, 90
QF (CHF) . 53, 55, 82, 91
DIA (CHF) m 70
IIC and EIC (COPD) m 92
HAD
QF (COPD) . 30, 90
QF (CHF) . 53, 55, 82, 91
DIA (CHF) m 70
IIC and EIC (COPD) m 92
SDH
QF (COPD) . 90
QF (CHF) . 53, 91
COX
QF (COPD) m 93
CCRT
QF (CHF) m 80
HK
QF (CHF) . 91
DIA (COPD) . 94
IIC and EIC (COPD) m 92
PFK
QF (COPD) m 90
LDH
QF (COPD) m 902
QF (CHF) m 822
DIA (CHF) . 70
DIA (COPD) . 94
IIC and EIC (COPD) . 92
1CS, citrate synthase; HAD,b-hydroxyacyl-CoA dehydrogenase;
SDH, succinate dehydrogenase; COX, cytochrome c oxidase; CCRT, NADH
cytochrome c reductase; HK, hexokinase; PFK, phosphofructokinase; LDH,
lactate dehydrogenase; QF, quadriceps femoris; DIA, diaphragm; IIC, inter-
nal intercostal; EIC, external intercostal.
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found in skeletal muscle tissue (138, 139). In addition, in
myocytes obtained from chronically hypoxic human myocardium
cultured at low oxygen tension, antioxidant enzyme activities
were lower than in myocytes cultured at a higher oxygen tension,
illustrating the direct modulatory effect of oxygen (140). In vivo
and in vitro hypoxia-reoxygenation studies showed that oxygen
oversupply after a period of oxygen shortage may give rise to
free radical formation in myocytes (138, 141, 142). Accordingly,
in COPD and CHF patients, chronic hypoxia may result in
reduced antioxidant status and occasional bouts of exercise may
cause a burst of free radicals that exceeds the capacity of the
defense system (122). It is also possible that the patients’ reduced
oxidative capacity itself leads to enhanced oxidative stress
because the sudden oversupply of oxygen during exercise is inef-
ficiently metabolized.
Reactive oxygen species are capable of damaging lipids and
proteins (122, 123, 134, 143). Radicals that react with fatty acyl
moieties in membrane phospholipids cause a chain reaction of
peroxidations that increase the membrane permeability (143).
Maintenance of membrane integrity is crucial for adequate func-
tioning of the respiratory chain because the driving force for
oxidative ATP synthesis is the electrochemical proton gradient
over the inner membrane of the mitochondrion, which is gener-
ated during the electron transfer from NADH to oxygen (96).
Leakage of ions through a more permeable mitochondrial inner
membrane may thus impair mitochondrial function by uncou-
pling oxidative phosphorylation. Indeed, rats with an inherited
overproduction of oxygen free radicals showed a higher degree
of lipid peroxidation and protein damage in combination with
impaired respiratory chain function in liver mitochondria than
did control rats (144). Furthermore, a marked decrease in ATP
concentrations was observed in cultured endothelial cells
exposed to reactive oxygen species (145). In addition, there is
evidence that an intracellular calcium overload, probably caused
by a damaged sarcoplasmic reticulum membrane in combination
with impaired activity of calcium ATPases, accompanies oxida-
tive stress in animal myocytes (122, 138, 141, 142, 146–148),
which may further uncouple respiration from ATP production
through extensive depolarization of the inner membrane (149).
Protein oxidation by oxygen free radicals leads to formation
of carbonyl groups on amino acid residues, which may modify
the structure or chemical properties of the proteins affected
(150). These alterations may cause a decline in protein function
or even complete protein unfolding. The latter gives rise to
enhanced susceptibility to proteinases. These modified proteins
may also be recognized as foreign substances and, hence, be
attacked by the immune system. Whether radical-induced pro-
tein damage plays a role in the abnormalities in muscles of
COPD and CHF patients is unclear. It was shown in animal
studies that oxidative stress induced in vivo caused myofibrillar
muscle protein modification and that these proteins were rapidly
degraded by proteases (151). Thus, theoretically, muscle atro-
phy can be enhanced by radical-induced protein damage.
Indeed, it was shown that a calcium overload is involved in mus-
cle atrophy (152) and that vitamin E deficiency facilitates mus-
cle wasting and necrosis (153), both probably mediated by
oxidative damage to proteins. Also, in human skeletal muscle it
was shown that mitochondria and mitochondrial proteins were
more susceptible to oxidative damage than were other subcellu-
lar components (154), which suggests that protein damage may
cause impaired oxidative metabolism.
As opposed to necrosis, which is the result of exogenous dam-
age as described above, apoptosis of muscle cells is an active
process of cell death, which has also been associated with oxida-
tive stress (155). In this study, the exposure of rat myoblasts to
nitric oxide or hydrogen peroxide led to apoptotic cell death.
Because these chemical stimuli are also released by immune
cells, we cannot exclude the possibility that apoptosis underlies
muscle wasting during inflammation.
Disuse
Disuse of skeletal muscle from a low level of physical activ-
ity is also a factor that most likely contributes to the observed
muscle alterations in COPD and CHF. Hampered by their dis-
ease, these patients perform less physical activity, which may
have a detraining effect on their peripheral muscles. First,
detraining causes muscle weakness because of reduced motor
neuron activity and muscle wasting (59, 156). Second, disuse
may cause a relative reduction in the percentage of type I fibers
and an increase in the percentage of type IIb/x fibers (59, 157).
Third, detraining causes a decline in the activity of enzymes
involved in oxidative energy conversion. This occurs in both type I
and type II fibers (157, 158), suggesting that loss of oxidative
capacity can occur even without any change in fiber composi-
tion. As mentioned earlier, muscular disuse has a negative effect
on antioxidant status and, hence, enhances the risk of oxidative
damage. Reduced physical activity thus contributes to the loss of
muscle mass and probably also to the I→II fiber shift and the
reduced oxidative capacity observed in limb muscles in COPD
and CHF patients. As mentioned above, the diaphragm is proba-
bly not disused in these diseases and a kind of endurance train-
ing effect may even occur. This may be true not only for COPD
but for CHF as well because in severe CHF, dyspnea and ele-
vated ventilation occurs even at rest (28, 159).
Medication
Of the wide range of drugs used to treat COPD and CHF, only
corticosteroids have been associated with skeletal muscle alter-
ations. Especially in COPD, but less frequently in CHF, corticos-
teroids are used in low doses as maintenance medication or in
higher doses during acute disease exacerbations (160, 161).
Depending on the type of steroid, the dose, and the duration of
treatment, the drug-induced defects range from alterations in
energy metabolism to muscle weakness with underlying muscle
wasting and histologic abnormalities (160, 161). From the results
of both clinical and animal studies it became clear that steroid-
induced muscle wasting is often associated with an overall negative
nitrogen balance, reduced protein synthesis, increased protein
catabolism in muscle tissues, and increased plasma concentrations
of amino acids (162). These findings suggest that corticosteroids
probably stimulate the mobilization of amino acids from muscle
proteins (161), supplying the liver with gluconeogenic precursors,
which corresponds with a shift toward glycolytic metabolism. No
such data are available for CHF, but a few reports showed that
COPD patients who chronically receive corticosteroids indeed may
show more muscle weakness alone or with an accompanying loss
of muscle mass than do nontreated COPD patients (17, 163–165).
However, because COPD patients receive corticosteroids to treat
inflammation, it is difficult to distinguish between the effect of
steroid administration and the effects of the disease exacerbations.
Also, decreased testosterone concentrations have been reported for
male COPD patients receiving glucocorticoids (166).
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Assuming that corticosteroids are involved in muscular alter-
ations, the question arises as to whether this effect is generalized
or is muscle-type specific. Experimental studies indicate that the
glycolytic fibers seem especially susceptible to steroid-induced
muscle wasting (161, 162, 167), suggesting that vulnerability
depends on muscle fiber composition. The diaphragms of affected
patients have a relatively high proportion of type I fibers, and so
could therefore be less affected by steroid usage; limb muscles,
consisting of more type II fibers, would be more vulnerable. On
the other hand, the diaphragm already has a lower type II fiber
content and selective wasting of type II fibers could further
reduce diaphragm strength. Because strength is the main limiting
factor in diaphragm muscle performance, it may be more vulner-
able to corticosteroids than are limb muscles. Furthermore, it is
difficult to isolate the effect of corticosteroids on diaphragm
function from the complex of other unfavorable influences on
lung function in COPD (165). Therefore, Wang et al (168) stud-
ied the effect of prednisone on the respiratory muscle function of
normal subjects (who had no disturbing influences on function)
and found no differences from a control group. This does not
exclude the possibility that other steroids might have an effect
because a recent animal study showed different effects of fluori-
nated and nonfluorinated steroids at equipotent doses (169). The
results of other animal studies confirm the hypothesized shift
toward glycolytic metabolism in peripheral muscle and the shift
toward oxidative metabolism in the diaphragm: in corticosteroid-
treated rats it was found that diaphragm force generation and the
proportion of type IIb fibers was reduced in combination with
decreased activity of the glycogenolytic enzyme phosphorylase
and increased activities of HAD and citrate synthase (170).
Increased phosphofructokinase and glycogen synthase activities
have been reported for limb muscle of corticosteroid-treated rats
(169). Expressed per gram of muscle, limb twitch tension may
even increase in steroid-treated animals, which indicates an
increase in type II fiber content (169, 171). The fact that corti-
costeroids selectively affect type II fibers but are also associated
with a shift toward glycolytic metabolism in peripheral muscle
seems contradictory and needs further investigation.
Note that in both CHF and COPD, muscle performance is not
fully recovered 5–38 mo after heart or lung transplantation; intrin-
sic skeletal muscle alterations remain (57, 172). Corticosteroids
and cyclosporin are often used as immunosuppressive agents after
transplantations and it is therefore possible that these drugs might
be involved in impaired muscle function (13, 57, 172).
Nutritional depletion and systemic inflammation
Nutritional depletion commonly occurs in COPD (173, 174)
and CHF (42, 175). In both disorders, nutritional depletion is an
important determinant of exercise capacity (3, 44, 45, 176).
Body weight (usually corrected for height) is often used to deter-
mine the nutritional status of patients, but this method neglects
the differences in body composition between individuals (3).
Determination of body composition with respect to nutritional
depletion is important because different patterns of weight loss
can be distinguished: predominant loss of fat mass, predominant
loss of fat-free mass, or a combination of both.
Predominant loss of fat mass involves an impaired balance
between energy requirements and energy intakes. Dietary intake
can be low in COPD because of symptoms such as dyspnea,
fatigue, and early satiety (177). Recently, systemic inflammation
was suggested to affect appetite and dietary intake, mediated by
the appetite-regulating hormone leptin (178). However, patients
with COPD may lose weight despite a normal or above-normal
dietary intake (179). In COPD and CHF, resting energy expendi-
ture (REE) is often elevated (180–183). In addition, total daily
energy expenditure that is elevated independently of REE has
been found in COPD patients (184). Increased oxygen cost of
breathing probably contributes to the increased total daily energy
expenditure due to increased hyperinflation during exercise
(185, 186), but because hyperinflation is not increased at rest, it
is unlikely that an elevated oxygen cost of breathing accounts for
the elevated REE (180). Suggested contributors to the elevated
REE are the thermogenic effects of bronchodilating agents (180)
and systemic inflammation (127). Furthermore, the observed
loss of efficient aerobic energy metabolism might play a role in
the increased REE and total daily energy expenditure. In this sit-
uation of semistarvation, loss of both fat mass and fat-free mass
occurs, but the fat-free mass is relatively preserved. Therefore,
intrinsic muscle abnormalities besides muscle mass probably
account for impaired muscle performance.
Studies of muscle function and histology in anorexia nervosa
patients have provided strong data on the effect of undernutrition
n muscles. Muscle performance is markedly impaired in these
patients (187–189) and is associated with weight loss, loss of
muscle mass, and fiber atrophy (particularly of type II fibers)
(190, 191). Data from animal studies confirm these effects of
undernutrition. Loss of muscle mass associated with fiber atrophy
was observed in limb muscles during nutritional deprivation (171,
192). Activities of the oxidative enzymes succinate dehydroge-
nase and HAD were found to be reduced (192, 193). The activity
of the glycolytic enzyme phosphofructokinase was also found to
be reduced (193), but this was not confirmed by Koerts-de Lang
et al (169). In addition, high ADP and low CrP concentrations
were observed in food-deprived animals (193, 194), suggesting
that muscle energy metabolism is indeed impaired after depriva-
tion. However, it remains unclear whether nutritional deprivation
results in a general loss of activities of enzymes involved in
energy metabolism or predominantly affects either oxidative or
glycolytic energy metabolism. The contribution of nutritional
depletion to a shift from oxidative to glycolytic metabolism in
COPD and CHF patients needs further investigation.
Predominant loss of fat-free mass involves an impaired bal-
ance between protein anabolism and catabolism that results in
the loss of fat-free mass. In emphysema, reduced muscle protein
synthesis was found (49), but protein degradation was probably
not increased (195, 196). Also, nitrogen intake was not low in
these patients but nitrogen excretion was elevated (196). Amino
acids may be required in processes other than muscular protein
synthesis, such as gluconeogenesis. Because weight loss and loss
of fat-free mass have often been associated with systemic
inflammation in both COPD and CHF (126, 127, 133), it is also
possible that amino acids are required for increased synthesis of
inflammatory proteins in the liver. Disturbed plasma and muscle
amino acid concentrations have been observed in COPD, sug-
gesting that amino acids are indeed redirected from muscle (197).
Animal and in vitro studies confirm this notion (198): exposure of
myocytes to TNF-a resulted in a decrease in protein synthesis,
which occurred even during anabolic stimulation with insulin-
like growth factor I (IGF-I). Furthermore, chronic administration
of TNF-a led to increased muscle protein catabolism and liver
protein anabolism in rats. In addition, the above-mentioned
involvement of TNF-a in oxidative stress may contribute to mus-
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cle wasting (125). Protein depletion itself may impair skeletal
muscle performance as reflected by reduced maximum voluntary
handgrip strength, reduced respiratory muscle strength, and




It is obvious that exercise training improves muscular perfor-
mance because, depending on the training program, strength,
endurance, or both improve (59). Because disuse has been sug-
gested to be an important factor responsible for the alterations
in muscle metabolism in COPD and CHF, it is possible that
training the affected muscles could reverse these abnormalities.
Indeed, exercise training improves exercise capacity in both
COPD (200, 201) and CHF (6, 43, 202) patients. Furthermore,
increased cross-sectional areas of oxidative fibers and elevated
oxidative enzyme activities in the quadriceps muscle in combi-
nation with less arterial lactate accumulation during exercise
have been found in trained COPD patients (46, 203). Training-
induced increases in oxidative capacity and muscle mass of the
quadriceps muscle have also been reported for CHF patients
(58, 87). The above-mentioned exercise-induced increase in
the Pi-CrP ratio and drop in pH in muscle is less after train-
ing (202). Thus, in peripheral muscles, training induces a
partial improvement of the oxidative capacity in combination
with increased exercise performance. In general, prolonged
endurance training leads to increased percentages of type I and
IIa fibers accompanied with greater oxidative capacity, result-
ing in higher fatigue resistance (59). Therefore, considering
that fatigue is the main limiting factor in peripheral muscle per-
formance, an endurance training protocol may be most suitable
for improving the exercise capacity of limb muscles in COPD
patients. This is also illustrated by the fact that in COPD
patients, quadriceps endurance shows a larger improvement
with training than does strength (200, 201).
No data on improvement of oxidative capacity with training
are available for respiratory muscles. However, the differences
between respiratory and peripheral muscles in COPD and CHF
suggest that different training approaches are required to effec-
tively improve their performances. Whereas respiratory muscle
training in CHF remains an unexplored field, a variety of stud-
ies have been performed for COPD (204). Although training of
respiratory muscle may improve its performance, there is little
evidence of real clinical benefit. The best results are probably
obtained with so-called resistance training (204), in which the
inspiratory muscles are subjected to an increased pressure load.
The fact that this is a kind of power training affecting respira-
tory muscle strength especially suggests that training of the
diaphragm should be more focused on strength than on
endurance (205, 206).
Another possible positive effect of exercise training is the
increase in antioxidant status. As discussed above, disuse (or
“disuse hypoxia”) has a negative effect on antioxidant status and
may therefore promote oxidative damage during occasional exer-
cise because of the temporarily enhanced oxygen supply to the
exercising muscles. However, regular physical exercise involves
a regular increase in exposure of muscle tissue to oxygen and
training thus probably reduces the risk of oxidative stress (135).
Nutritional support, anabolic steroids, and antiinflammatory
therapy
The effects of nutritional support strategies on muscle mass
and muscle function have been investigated in COPD, but it is a
relatively unexplored area in CHF. Several studies in nutritionally
depleted patients with COPD have shown that nutritional supple-
mentation can improve both respiratory and peripheral muscle
function (174, 207, 208). It is unclear, however, to what extent
this improvement in muscle function is related to the increase in
muscle mass per se (209). Muscle performance may reach normal
values with nutritional support while muscle mass is still lower
than that of control subjects, as shown for example in anorexia
nervosa patients (189), which suggests that repletion of intrinsic
muscle abnormalities is important in the improvement of muscle
function. An early and a late response to nutritional supplementa-
tion has been proposed (199). After the first few days of repletion,
muscle function improves 10–20% without any demonstrable
gain in tissue protein. This early response probably results from
improved electrolyte content (210) and improved concentrations
of energy-rich compounds (51, 199). Only during prolonged
treatment do physiologic functions further improve, accompanied
by an increase in tissue protein and muscle mass (211).
However, a substantial subgroup of COPD patients did not gain
weight in response to high-energy nutritional therapy (212). This
subgroup was characterized by an elevated systemic inflammatory
response, as evidenced by high concentrations of acute phase pro-
teins and soluble TNF receptors. As mentioned earlier, systemic
inflammation is associated with protein catabolism and probably
plays a role in the loss of muscle mass. This suggests that antiin-
flammatory therapy might be beneficial in this particular subgroup.
Many COPD patients receive inhaled or oral corticosteroids to
treat local inflammation and acute infections. Systemic inflamma-
tion, however, is not reversed during this treatment (213). In addi-
tion, oral steroids may have a negative effect on skeletal muscle as
mentioned above. A possible way to modulate systemic inflamma-
tion is through ingestion of polyunsaturated fatty acids (PUFAs).
PUFAs are incorporated into the phospholipids of the cell mem-
brane and play an important role in the regulation of inflammatory
processes. Indeed, fish-oil supplementation reduced inflammatory
mediators and had an anticachectic effect in pancreatic cancer
patients (214). No studies are yet available regarding PUFA sup-
plementation in COPD or CHF.
Administration of anabolic steroids may be an additional
mode of intervention to counteract protein catabolism either
by the androgen receptor–mediated promotion of protein
anabolism or by neutralizing the effects of glucocorticosteroids
through binding competition for the receptor mediating catab-
olism (215). Anabolic steroids could thus be useful in patients
with muscle wasting, especially in those who are treated with
corticosteroids. Anabolic steroid treatment in addition to nutri-
tional support as an integrated part of a pulmonary rehabilita-
tion program produced significantly enhanced fat-free mass
despite a similar weight gain with nutritional support only. This
increased fat-free mass was reflected in improved respiratory
muscle function (209, 216). No difference in response was
noted for patients receiving maintenance oral corticosteroid
treatment (209). Currently, the effects of this combined treat-
ment approach on peripheral skeletal muscle function, exercise
performance, and health status is being studied. Besides effects
on muscle performance, anabolic steroids resulted in an
improvement in negative acute phase proteins such as albumin
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and transthyretin (215) in depleted COPD patients. This may
indicate an antiinflammatory effect.
Others have investigated the effects of adjuvant treatment with
recombinant human growth hormone (rhGH). Administration of
this hormone induces lipolysis, protein anabolism, and muscle
growth, either directly or through IGF-I. Two uncontrolled stud-
ies showed the effects of rhGH in nutritionally depleted patients
with COPD. Administration of rhGH for 8 d (0.03 mg·kg21·d21
subcutaneous for 4 d, plus 0.06 mg·kg21·d21 for another 4 d) did
not increase respiratory and peripheral skeletal muscle strength
in COPD (217). In contrast, an increase in inspiratory muscle
strength was reported after 3 wk of treatment (0.05 mg·kg21·d21
subcutaneous) (218). With use of a similar treatment regimen, but
in a placebo-controlled fashion, the effects of administration of
rhGH on body composition, resting metabolic rate, and functional
capacity in underweight COPD patients in a stable clinical state
were studied (219). Although fat-free mass increased signifi-
cantly during the 3-wk treatment period, no improvement was
seen in muscle function and exercise capacity even decreased in
the treatment group. Furthermore, a significant increase in resting
metabolic rate was observed.
In the previous sections of this article, we stated that COPD
and CHF patients may have increased oxidative stress, in either
muscle or lung tissue. Furthermore, vitamin E deficiency is asso-
ciated with the pathogenesis of the wasting and weakness in tha-
lassemia major (220). Therefore, another mode of nutritional
intervention might be supplementation with antioxidants such as
vitamins, glutathione, and N-acetylcysteine. Several studies
indeed showed a beneficial effect on wasting of antioxidant sup-
plementation (221). For example, vitamin E protects human
skeletal muscle from damage during surgical ischemia-reperfu-
sion (222) and vitamin C supplementation reduces exercise-
induced oxidative stress (223). Similar results have been obtained
in animal studies (153, 224, 225). Although antioxidant supple-
mentation does reduce physical exercise–induced oxidative
stress, it remains unclear whether exercise performance is
enhanced (134, 221). Most of these data were obtained from ath-
letes, who already have a high exercise capacity, whereas vitamin
supplementation may have more effect in COPD and CHF
patients, who have a very low exercise capacity. In addition, there
are some indications that vitamin supplementation may improve
lung function (226, 227). Antioxidant administration in CHF and
COPD therefore deserves further investigation.
Oxygen therapy
Long-term oxygen therapy (LTOT) improves survival and
quality of life of COPD patients (228, 229), but no such data are
available for CHF. It is clear that acute oxygen administration is
beneficial for exercise capacity in COPD (230–232). However,
very little is known about the ability of LTOT to reverse the alter-
ations found in skeletal muscles of COPD patients. In fact,
improved exercise capacity during oxygen administration,
including LTOT, could very well be an acute effect with no
reversal of these abnormalities. First, by supplying oxygen,
hypoxemia is partly reversed and with that dyspnea may be
improved (230). The latter is an important determinant of exer-
cise tolerance in COPD. Therefore, relief of breathlessness may
account for a great deal of improvement in exercise capacity
(231). Second, the acute supply of oxygen to muscle tissue prob-
ably improves oxidative energy metabolism only during the oxy-
gen administration period itself, because the indexes of oxidative
energy metabolism (Pi-CrP, pH, and CrP recovery) showed some
improvement in a group of COPD patients only during oxygen
administration (85). After exercise while breathing room air,
COPD patients receiving LTOT still had a low Pi-CrP ratio and
low pH in combination with slow CrP recovery compared with
control subjects. Also, supplementation of oxygen does not add
to the improving effects of training (232). Only in one study was
there a reported improvement of the CrP-(CrP + Cr) ratio in rest-
ing muscle of COPD patients while breathing room air after
6–9 mo of LTOT (233). However, because the partial pressure of
oxygen in blood also improved, this increase was probably
caused by an increased oxygen supply and was not due to any
reversal of muscle abnormalities. In addition, the low glycogen
concentrations failed to improve, which further suggests that the
muscle abnormalities were not reversed.
Little attention has been paid to lung damage from oxidative
stress with respect to oxygen administration. It is clear that free
radicals play an important role in the development of COPD,
because 90% of all patients are exsmokers and cigarette smoke is
a rich source of oxidants that cause all sorts of lung damage (234).
The concentrations of oxygen administered to COPD patients are
potentially toxic and may also result in lung injury caused by
oxidative stress (235, 236). More research needs to be done to
establish whether oxygen administration is beneficial or may con-
tribute to lung or even peripheral tissue damage. In the meantime,
if oxygen supplementation is necessary, it is recommended that
the lowest effective concentration of oxygen be used (236).
CONCLUSIONS
This review underscores the fact that reduced skeletal muscle
performance contributes markedly to exercise intolerance in
COPD and CHF patients. Morphologic and metabolic abnormal-
ities occur in the skeletal muscles of these patients which, in
both disorders, are probably determined by the same set of con-
tributing factors, including hypoxia, oxidative stress, disuse,
medication, nutritional depletion, and systemic inflammation.
Both diseases also share striking differences between peripheral
muscles and the diaphragm, which may therefore require differ-
nt therapeutic approaches. Future investigations of the mecha-
nisms and relative contributions of each of the factors leading to
these intrinsic muscular alterations are required.
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